Mergers & Acquisitions ·
Jasper Therapeutics reported second quarter 2026 financial results and provided a corporate update
JSPRWJasper Therapeutics, Inc.
Jasper Therapeutics reported second quarter 2026 financial results and provided a corporate update. The company completed the acquisition of Kira Pharmaceuticals in July 2026 via an all-stock transaction, creating a combined entity with a robust portfolio for immune-mediated diseases. Concurrently, Jasper raised $132 million in gross proceeds through a private placement of non-voting convertible preferred stock. As of June 30, 2026, the company held $7.3 million in cash and reported a net loss of $2.8 million, or $0.10 per share. The combined company plans to advance lead asset KP-104, progress briquilimab toward a potential BLA, and commence first-in-human studies for KP-701. Jasper Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for immune-mediated diseases.